1. Effects of Methylphenidate on Fatigue and Depression: A Randomized, Double-Blind, Placebo-Controlled Trial 
Christopher W. Kerr, MD, PhD, Julie Drake, PharmD, Robert A. Milch, MD, FACS, Daniel A. Brazeau, PhD, Judith A. Skretny, MA, Gayle A. Brazeau, PhD, James P. Donnelly, PhD 
Journal of Pain and Symptom Management 
Volume 43, Issue 1, Pages (January 2012)
DOI: /j.jpainsymman
Copyright © 2012 U.S. Cancer Pain Relief Committee Terms and Conditions

2. Fig. 1 Flow diagram of study phases.
Journal of Pain and Symptom Management  , 68-77DOI: ( /j.jpainsymman )
Copyright © 2012 U.S. Cancer Pain Relief Committee Terms and Conditions

3. Fig. 2
Comparison of mean fatigue scores for placebo- and MP-treated groups according to three indices of fatigue. Results reported as mean fatigue scores at baseline (Day 0), Days 3, 7, and 14. Key: a=significantly different between Days 0 and 14 with P<0.05; b=significantly different between placebo and control with P<0.05.
Journal of Pain and Symptom Management  , 68-77DOI: ( /j.jpainsymman )
Copyright © 2012 U.S. Cancer Pain Relief Committee Terms and Conditions

4. Fig. 3
Comparison of Piper Fatigue subscale scores for placebo- and MP-treated groups. Results reported as percent change from baseline at Days 3, 7, and 14. Key: a=significantly different between Days 0 and 14 with P<0.05; b=significantly different between placebo and control with P<0.05.
Journal of Pain and Symptom Management  , 68-77DOI: ( /j.jpainsymman )
Copyright © 2012 U.S. Cancer Pain Relief Committee Terms and Conditions

5. Fig. 4
Comparison of mean scores for placebo- and MP-treated groups according to three indices of depression. Results reported are mean average depression scores at baseline (Day 0), Days 3, 7, and 14. Key: a=significantly different between Days 0 and 14 with P<0.05; b=significantly different between placebo and control with P<0.05.
Journal of Pain and Symptom Management  , 68-77DOI: ( /j.jpainsymman )
Copyright © 2012 U.S. Cancer Pain Relief Committee Terms and Conditions